Abstract
Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Current Bioinformatics
Title: Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Volume: 6 Issue: 1
Author(s): Francisco Prado-Prado, Manuel Escobar-Cubiella and Xerardo Garcia-Mera
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Abstract: Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Prado-Prado Francisco, Escobar-Cubiella Manuel and Garcia-Mera Xerardo, Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors, Current Bioinformatics 2011; 6 (1) . https://dx.doi.org/10.2174/157489311795222428
DOI https://dx.doi.org/10.2174/157489311795222428 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis
Current Alzheimer Research Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Design, Synthesis and Biological Evaluation of New Cycloalkyl Fused Quinolines Tethered to Isatin Schiff Bases as Cholinesterase Inhibitors
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology Cognitive Reserve in Aging
Current Alzheimer Research A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia
Current Alzheimer Research Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Radiotracers in Oncology
Current Radiopharmaceuticals Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease
Current Alzheimer Research β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Antioxidant Pathways in Alzheimers Disease: Possibilities of Intervention
Current Pharmaceutical Design Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening